The PI3K/AKT and MAPK pathways are frequently activated in cancers, including KRAS mutant NSCLCs, and around 30% of adenocarcinomas (ACs) and 3% of squamous cell carcinomas (SCCs) contain KRAS mutations14. The gene discussed is KRAS; the disease is adenocarcinoma.